¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º U `lp56  
Kf? :dF  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ OGW3Pe0Z'  
I@qGDKz;  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ;mI^J=V3  
,dd1/zm  
1. ICAM-1 !5'4FUlJ  
By9CliOy:  
2. interleukin 12(IL-12) d %FLk=]  
$[Ut])4 ~  
3. tumor infiltrating lymphocyte B&7:=t,m(  
gKQs:25  
4. TCR/CD3 complex fVZ9 2Xw B  
: &n F>  
5. hematopoietin receptor family amExZ/  
Q(Yn8t  
6. individual idiotype(IdI)  2rC&  
d"E3ypPK  
7. integrin = [: E  
7K&Uu3m  
8. colony-stimulatory factor (CSF) /oJ &\p I  
:+w6 i_\d5  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© #=0 BjW*  
O8>&J-+2  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? )/[L)-~y~  
Yv)c\hm(7j  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ShlTMTgS  
F?jD5M08t/  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ*ZLisq-f  
8QL=%Pv  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ \ qq  
VR1[-OE  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) z Fj|E  
\et2aX !  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ tcRJ1:d  
(C uM*-  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) MwQ4&z#wh  
yZm= #.f  
3. immunoglobulin superfamily (IgSF)  /d!  
\RPwSx  
4. selectin T>b"Gj /  
]a uqf  
5. anti-idiotypic antibody (¦ÁId) _emW#*V  
vGPsjxk&  
6. major histocompatibility complex(MHC) ZQ*Us*9I  
kw#-\RR_c  
7. immunotolerance |6^%_kO!|  
7Nk|9t  
8. biological reponse modifier(BRM) P7Qel,  
v4'kV:;&  
9. immune reponse gene (Ir gene) n|rKo<Y0  
`]@=Hx(  
10. reshaped antibody (or reconstituted antibody) PXJ7Ek*/  
|S |'o*u  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© I_->vC|>  
tk=S4 /VWv  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ t#t[cgI  
xh9$ZavB*  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? XG C\6?L~  
f^u-Myk  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ K5XW&|tY!  
C&*1H`n  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? J,u-)9yBA<  
2u!&Te(!9  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ pPo xx"y  
y5+%8#3  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 7C3YVm6g  
n;N79`mZC  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Rc1k_fZ}  
bGgpPV  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ nM b@  B  
h ! R=t  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? ,#&7+e!]>P  
y*-_  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 'EXx'z;/#  
]SRpMZ  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: PS[ C!s&KE  
"z3rH~q72  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: &s(&B>M  
Cgh84 2%  
ÃâÒßѧ x4H#8ZK!  
Uza '%R  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 0Q_*Z (  
bD:0k.`  
1. CD8 RLnL9)`W  
A&~fw^HM  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) W_Y8)KxG:L  
S\&3t}_  
3. immunoglobulin fold(Ig fold) ty0P9.Q  
U"p</ Q  
4. cadherin (Ca-dependent cell adhesion moleculers) X(nyTR8  
c8JW]A`9b)  
5. idiotype-anti-idiotypic antibody immune network theory Q,xL8i M,  
GN(<$,~g  
6. HLA class II antigen _2 hLc\#  
1Qf}nWy  
7. complementarity-determining region (CDR) ,=m.WmXE  
qMNW w\k  
8. perforin(or pore-forming protein ,PFP) UPfO;Z`hJ  
x [FLV8`b|  
9. high affinity IL-2 receptor "+"=iwEAz  
EE!}$qOR  
10. artificial active immunization <'I["Um  
U4pIRa)S  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 7mi!yTr}  
|:=o\eu&  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠEMW6'  
@y aFN>w  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ?0VR2Yb${b  
85GIEUvH/  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ !LI<%P)  
q!5:M\  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ fe?Z33V  
`a& kD|Yh  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 2@D`^]]  
u]J@65~'b  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? Pd*[i7zhC  
_>;Wz7  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ fGo4&( U  
6Xlzdt  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 9)q3cjP{<  
&_ekA44E  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ a:h<M^n049  
I{`70  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ S\ k<  
T # \  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ji"g)d6  
ISbs l =F  
1. immunoglobulin gene rearrangement SUncQJJ0S*  
7F^d-  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) gE-y`2SU  
h+f>#O+:  
3. flow cytometry(FCM) 6OES'3Cy  
n_8[bkbi  
4. carrier effect a&y^Ps6=  
kI\m0];KnQ  
5. positive selection of T lymphocytes in thymus N%y i4  
DDg\oGLp  
6. mouse TH1(Th1) and TH2(Th2) subsets %`vzQt`>  
Hd|l6/[xz  
7. perforin (pore-forming protein ,PFP) Ac7^JXh%  
5\-uo&#  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) qt GJJ#^,  
( ?V`|[+u  
9. SH-2(src-homology region 2) vh9* >[i  
`+J Fvn!  
10. Ab2¦Â (internal image)  6 K $mW  
,b+NhxdZ  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© CUA @CZ6{  
x%P|T3Qy5  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? 30Yis_l2h  
D7ex{SVA)  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? ?mQ^"9^XS  
eE;tiX/  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠJ3Mb]X)_}  
d1/emwH  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ +Qs]8*^?;  
:NzJvI<  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠbRC243]g*A  
A=CeeC]}  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) )fH Q7  
mgxIxusR  
ÃâÒßѧרҵ£º ><%585  
C \ Cc[v  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ Vla,avON  
l}{{7~C`  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? ;r h.6Dl  
:-&|QVH  
´«È¾²¡Ñ§×¨Òµ£º LyUn!zV$(  
1I Yip\:lS  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 4" @<bKx  
+qxPUfN  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ b`0tfXzS5  
J5@08 bZm  
Ïû»¯×¨Òµ£º 5'lVh/  
vwR_2u  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ $QX$rN  
npP C;KD  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? nx9PNl@?V  
F<4rn  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ #86N !&x  
gv!8' DKn  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ~z[`G#dU  
`At.$3B  
1. Fas(CD95)/FasL MB}nn&u#  
AbU`wr/h 4  
2. common chain of cytokine receptor %V_ XY+o  
5C w( 4.  
3 . TCR/CD3 complex .X g.,kW  
Sn:>|y~  
4. negaive selection of thymocytes 0AZ9I!&i  
1=VyD<dNG6  
5. artificial active immune OM'iJB6=  
x/ QqG1q  
6. anti-idiotypic V:0IBbh)w  
YOxgpQ:i  
7. IgSF B=Hd:P|  
5!0iK9O  
8. Integrin 2:LUB)&i  
)! [B(  
9. chemokine z:'m50'  
WC_.j^sW  
10. B7/CD28 b1xE;0uR  
KFM[caKeJO  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© N'1I6e"  
y"?`MzcJ0  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ +U f w  
D5zc{) /  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ :?f<t NU$  
U$:^^Zt`B  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ a[ULSYEi  
z$<=8ox8e  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ v]JET9hY  
BKFO^  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ &Vj @){  
[[T7s(3  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ g}9 ,U&$]y  
.+7n@Sc  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© y)r`<B  
XT0-"-q  
1. B7/CD28 {\Pk;M{Y&  
[_ N1 .}e  
2. Th1 subset l6zAMyau5  
cfmwz~S6i  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© e`Yj}i*bx]  
>A )Sl'  
4. antibody affinity maturation AyJl:aN^  
e_-g|ukC  
5. AP-1 F%L"Q>aHW  
U" @5R[=F-  
6. single chain variable fragment£¨ScFv£© fwpp qIM  
( w4XqVT  
7. NK cell receptor X&Oo[Z  
s-#@t  
8. Zinkernagel-Doherty phenomenon ErN[maix#  
|A4B4/!  
9. Ig fold !19T=p/:$  
D[W ` q#W  
10. CD40/CD40L nA Nl9;G  
tE>F L  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© C,;?`3bH@  
zGe =l;  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ L^u|= 9  
yS)k"XNb  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ Zn1((J7  
ks$5$,^T2o  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Sw$&E  
%B&O+~  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ bSM|"  
=Q"thsR  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ kFJ]F |^7  
uP7|#>1%  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ y 2k's  
z@~Z Mk  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ mj9|q8v{+  
[L7 S`Z   
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© W9Us I  
 :A#'8xE/  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© $sL+k 'dY  
1 >_$O|dE  
1.Co-stimulators (or co-stimulating molecules) v&sp;%I6=  
GNG.N)q#C  
2.NK-kB CE183l\  
48gpXcc@|  
3.Immunoglobulin superfamily 1_~'?'&^  
T~>&m~} +  
4.antigen-presenting cell (APC) b9f5  
B^1jd!m  
5.death domain qztL M?iV  
]~WIGl"g  
6.CCR and CXCR aBF<it>  
y9:o];/  
7.Lectin (or mitogen) RvW>kATb_F  
5o|u!#6  
8.Clusters of differentiation, CD) TI'~K}Te  
B@3>_};Ct  
9.B7 family [s!cc:JR  
Io;26F""  
10.Cytotoxic T lymphocyte, CTL) 3'Z+PPd!  
Bsz;GnD|r  
11.IL-15 and IL-15 receptor (IL-15R) MU_ >+Wnf  
,wra f#UdP  
12.MHC restriction Y0OVzp9 b  
9;c]_zt  
13.Affinity-chromatography s&OwVQ<M  
"_&HM4%!  
14.Cyctosprin A, CsA @}N;C ..Y$  
M#>f:_`<  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) F9SIC7}uH  
<Gudx>I  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© g>R md[!/  
;c>Rjg&[  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 D#9W [6  
^coJ"[D  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ZGOI8M]@  
A&0sD}I\K  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ WS0RvBvb  
BPKeG0F7  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ,Gd8 <  
QSy#k~  
ÃâÒßѧרҵ£º !$5U\"M  
',* 6vbII  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ N|1k6g=0  
$NWI_F4  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Hca)5$yL  
7b T5-=.  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ 'bg%9}  
SR S~s  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) uoKC+8GA  
$y >J=  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) >[Q(!Ai  
bLoYg^T/  
1. ADCC(antibody dependent cell-mediated cytotoxicity) *-Y|qS%  
y?aOk-TaRA  
2. »·æß¾úËØ(cyclosporin) c66Iy"  
`h Y:F(  
3. KIR(killer cell inhibitory receptor) U1rh[A>  
+3t(kQ  
4. HLDA(human leucocyte differentiation antigen) Fu m1w  
7IZ(3B<87t  
5. Interleukin 18(IL-18) 4- 6'  
L1"X`Pz[}  
6. ÕûºÏËØ(integrin) P[ KJuc  
: ZU  
7. Fas/FasL m.EWYO0XQ  
})bTQj7  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ;Z.}~d6>!  
G m<t2Csn  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) I[<C)IG  
WFN5&7$W  
10. Th1/Th2 _.FxqH>  
S)$ES6]9/  
11. »ùÒòÒßÃç(DNAÒßÃç) =UNzjmP503  
+\.gdL)  
12. chemokines and chemokine receptor UwdcU^xt9  
eB!0:nHN  
13. ÃâÒßÄÍÊÜ Z^`>;n2  
XF{}St~(  
14. ¹²´Ì¼¤·Ö×Ó t91v%L   
,1F3";`n[  
15. ËÀÍö½á¹¹Óò(death domain) KH2a 2  
cD2}EqZ 9  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) { b+!0[  
tX Z5oG7  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? Alp9] 0(  
kV6T#RVob  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠC8@SuJ  
s'fHh G6  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î G4MNcy  
Suk RJvi  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ -5d8j<,  
F ~ /{1Q*  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå >K;p+( <6  
[D?RL `ZF  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ 3(}HD*{E[@  
z)yxz:E  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) ezCsbV;. [  
#U(dleT8  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 70a7}C\/o  
.0cm mpUNq  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ $ ;~G  
!ZD[ $lt+  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»